Chen Junru, Ni Yuchao, Sun Guangxi, Zhu Sha, Zhao Jinge, Wang Zhipeng, Zhang Haoran, Zhu Xudong, Zhang Xingming, Dai Jindong, Shen Pengfei, Zeng Hao
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Front Oncol. 2020 Nov 26;10:607576. doi: 10.3389/fonc.2020.607576. eCollection 2020.
We aimed to compare the efficacy of radical prostatectomy (RP) + extended pelvic lymph node dissection (ePLND) and radiotherapy (RT) in localized prostate cancer (PCa) patients with a risk of lymph node invasion (LNI) over 5%.
The Surveillance, Epidemiology, and End Results (SEER) databases were used to identify patients with PCa from 2010 to 2014. Propensity score matching (PSM) was performed to balance baseline characteristics between patients in different treatment groups. Kaplan-Meier curves and Cox regression were used to assess the effects of treatments on cancer-specific survival (CSS) and overall survival (OS).
Overall 20584 patients were included in this study, with 4,057 and 16,527 patients receiving RP + ePLND and RT, respectively. After PSM, patients with RP + ePLND had similar CSS (5-year CSS rate: 97.8% vs. 97.2%, P=0.310) but longer OS (5-year OS rate: 96.0% vs. 90.8%, P<0.001) compared to those receiving RT. When separating RT cohort into external beam radiotherapy (EBRT) group and EBRT+ brachytherapy (BT) group, treatments with RP + ePLND and EBRT+ BT achieved equivalent OS and were both superior to EBRT alone (5-year OS rate: 96.0% vs. 94.4% vs. 90.0%, P<0.001). Subgroup analyses and multivariate analyses further confirmed the superiority of RP + ePLND and EBRT+ BT.
RP + ePLND and EBRT + BT were associated with better survival outcomes compared to EBRT alone in PCa patients with a probability of LNI over 5%. However, no survival difference was observed between RP + ePLND and EBRT + BT.
我们旨在比较根治性前列腺切除术(RP)+扩大盆腔淋巴结清扫术(ePLND)与放射治疗(RT)对淋巴结侵犯风险(LNI)超过5%的局限性前列腺癌(PCa)患者的疗效。
利用监测、流行病学和最终结果(SEER)数据库识别2010年至2014年期间的PCa患者。进行倾向评分匹配(PSM)以平衡不同治疗组患者的基线特征。采用Kaplan-Meier曲线和Cox回归评估治疗对癌症特异性生存(CSS)和总生存(OS)的影响。
本研究共纳入20584例患者,分别有4057例和16527例患者接受RP+ePLND和RT治疗。PSM后,与接受RT的患者相比,接受RP+ePLND的患者CSS相似(5年CSS率:97.8%对97.2%,P=0.310),但OS更长(5年OS率:96.0%对90.8%,P<0.001)。将RT队列分为外照射放疗(EBRT)组和EBRT+近距离放疗(BT)组时,RP+ePLND和EBRT+BT治疗的OS相当,且均优于单纯EBRT(5年OS率:96.0%对94.4%对90.0%,P<0.001)。亚组分析和多因素分析进一步证实了RP+ePLND和EBRT+BT的优越性。
在LNI概率超过5%的PCa患者中,与单纯EBRT相比,RP+ePLND和EBRT+BT与更好的生存结果相关。然而,RP+ePLND和EBRT+BT之间未观察到生存差异。